Get the Stockscreener App
4.44
1.33%
-0.06
Pre-market:
4.49
0.05
+1.13%
Polypid Ltd stock is traded at $4.44, with a volume of 13,446.
It is down -1.33% in the last 24 hours and up +1.14% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$4.50
Open:
$4.5
24h Volume:
13,446
Relative Volume:
0.26
Market Cap:
$84.73M
Revenue:
-
Net Income/Loss:
$-34.17M
P/E Ratio:
-1.9616
EPS:
-2.2635
Net Cash Flow:
$-47.63M
1W Performance:
-3.90%
1M Performance:
+1.14%
6M Performance:
+15.93%
1Y Performance:
+58.57%
1-Day Range:
$4.365
$4.50
1-Week Range:
$4.28
$4.70
52-Week Range:
$2.44
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.44 | 84.73M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com Canada
PolyPid says late-stage surgery trial cut severe wound infections 64% - Stock Titan
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026 - RTTNews
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com Australia
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - markets.businessinsider.com
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global - Investing.com
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating - GlobeNewswire
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
In a Phase 3 surgery trial, PolyPid's antibiotic released for 32 days - Stock Titan
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - MarketBeat
PYPD Options Volatility — NASDAQ:PYPD - TradingView
PYPD Options Chain — NASDAQ:PYPD - TradingView
PolyPid (NASDAQ:PYPD) Stock Price Up 3.3%Still a Buy? - MarketBeat
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Can PolyPid (PYPD) Stock Beat Estimates | Price at $4.24, Down 3.42%Aggressive Growth Stocks - Newser
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):